Rakovina Therapeutics Inc. RKVTF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 325.60K | 323.70K | 697.80K | 391.50K | 877.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.14M | 1.08M | 1.29M | 1.19M | 2.04M |
| Operating Income | -1.14M | -1.08M | -1.29M | -1.19M | -2.04M |
| Income Before Tax | -1.25M | -1.22M | -1.36M | -1.29M | -2.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.25M | -1.22M | -1.36M | -1.29M | -2.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.25M | -1.22M | -1.36M | -1.29M | -2.11M |
| EBIT | -1.14M | -1.08M | -1.29M | -1.19M | -2.04M |
| EBITDA | -1.04M | -977.70K | -1.19M | -1.09M | -1.95M |
| EPS Basic | -0.05 | -0.06 | -0.06 | -0.06 | -0.13 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.08 |
| EPS Diluted | -0.05 | -0.06 | -0.06 | -0.06 | -0.13 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.08 |
| Average Basic Shares Outstanding | 24.41M | 22.13M | 21.18M | 21.15M | 15.91M |
| Average Diluted Shares Outstanding | 24.41M | 22.13M | 21.18M | 21.15M | 15.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |